Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Blood Pressure Drugs May Slow Deterioration of Alzheimer’s

12.10.2004


Certain blood pressure drugs may slow the deterioration of Alzheimer’s disease, according to a study published in the October 12 issue of Neurology, the scientific journal of the American Academy of Neurology.

Called angiotensin-converting enzyme inhibitors, or ACE inhibitors, the drugs are used to treat high blood pressure. Only ACE inhibitors that can penetrate the blood-brain barrier were shown to have the effect on Alzheimer’s. The blood-brain barrier is a natural protective mechanism that shields the brain from foreign substances.

The study involved 162 people in Japan living in long-term care facilities with mild to moderate Alzheimer’s disease and high blood pressure. The participants were divided into three groups. For one year, each group received either a brain-penetrating ACE inhibitor, a non-brain-penetrating ACE inhibitor, or another type of blood pressure drug, called a calcium channel blocker. Those in the brain-penetrating ACE inhibitor groups received one of two drugs – perindopril or captopril.



The participants’ thinking and memory skills were tested at the beginning of the study and again at the end. The thinking and memory skills of those who took the brain-penetrating ACE inhibitors declined only slightly over the year. The skills of those who took the other drugs declined significantly.

At the beginning of the study, the participants had an average score of about 20 on the exam. The scores of those on brain-penetrating ACE inhibitors declined by an average of .6 points. The scores of those on non-brain-penetrating ACE inhibitors declined by an average of 4.6 points. The average decline was 4.9 points for those on calcium channel blockers. “These brain-penetrating ACE inhibitors might have benefits not only for the prevention but also for the treatment of mild to moderate Alzheimer’s,” said study author Takashi Ohrui, MD, of Tohoku University School of Medicine in Sendai, Japan. “These findings are provocative and exciting, but the results must be replicated in carefully controlled, randomized, blinded studies,” said neurologist David Knopman, MD, of the Mayo Clinic in Rochester, Minn., who wrote a commentary on the study.

Knopman noted that the study has several limitations. The participants knew which drug they received, and the researchers were not blinded to which participants received which drug. Blind studies are considered more scientifically accurate, because bias cannot be introduced. Another weakness is that there is no way to tell whether one of the brain-penetrating ACE inhibitors was more effective than the other in slowing the effects of Alzheimer’s disease, Knopman said.

The researchers don’t know how the brain-penetrating ACE inhibitors work to slow the cognitive decline in Alzheimer’s. The brain-penetrating ACE inhibitors did not lower the blood pressure more than the other drugs in the study. Researchers have found more angiotensin-converting enzyme (ACE) in the brains of people with Alzheimer’s disease than people who don’t have the disease. The brain’s renin-angiotensin system controls blood pressure and may play an important role in learning and memory processes. “The ACE inhibitors may work directly on the renin-angiotensin system in the brain,” Ohrui said.

The American Academy of Neurology, an association of more than 18,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer’s disease, narcolepsy, and stroke.

| newswise
Further information:
http://www.aan.com

More articles from Health and Medicine:

nachricht Cystic fibrosis alters the structure of mucus in airways
28.06.2017 | University of Iowa Health Care

nachricht Mice provide insight into genetics of autism spectrum disorders
28.06.2017 | University of California - Davis

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Supersensitive through quantum entanglement

28.06.2017 | Physics and Astronomy

X-ray photoelectron spectroscopy under real ambient pressure conditions

28.06.2017 | Physics and Astronomy

Mice provide insight into genetics of autism spectrum disorders

28.06.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>